BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

Reuters

2024/12/18

Dec 18 (Reuters) - Krystal Biotech Inc KRYS.O:

KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL
MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY & TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVED

Source text: ID:nGNX3mDtjH

Further company coverage: KRYS.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492855541"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492855541\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492855541?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492855541","market":"us","top_or_hot":-1,"title":"BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Krystal Biotech Inc <span>KRYS.O</span>:</p><ul><li><p>KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER</p></li><li><p>REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL</p></li><li><p>MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY &amp; TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVED</p></li></ul><p>Source text: <span>ID:nGNX3mDtjH</span></p><p>Further company coverage: <span>KRYS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-18 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Krystal Biotech Inc <span>KRYS.O</span>:</p><ul><li><p>KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER</p></li><li><p>REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL</p></li><li><p>MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY &amp; TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVED</p></li></ul><p>Source text: <span>ID:nGNX3mDtjH</span></p><p>Further company coverage: <span>KRYS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUAQQS39:1","article_id":"2492855541","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492855541","pubTimestamp":1734528801,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung CancerDec 18 (Reuters) - Krystal Biotech Inc KRYS.O:KRYSTAL BIO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KRYS":"Krystal Biotech Inc."},"translate_title":"BRIEF-Krystal Biotech宣布在接受过大量预处理的晚期非小细胞肺癌患者中单药治疗活性的早期证据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":0.9},"content_text":"BRIEF-Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung CancerDec 18 (Reuters) - Krystal Biotech Inc KRYS.O:KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCERREPORTS 27% ORR AND 73% DCR IN NSCLC TRIALMAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY & TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVEDSource text: ID:nGNX3mDtjHFurther company coverage: KRYS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}